- BySeeking Alpha-
NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today...
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a...
The stock rally in 2012 has been characterized by a low-quality rally, or "dash for trash". I wrote here that investors were under-invested in equities and have been rushing for...
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security market. The Company’s lead product TPOXX is approved by the Unites States Food and Drug Administration (FDA) as a drug with an indication for treatment of smallpox. TPOXX is an oral formulation, which is also known as tecovirimat and ST-246. The Company is developing the intravenous (IV) formulation for patients who are unable to swallow oral capsules. It is also focused on developing post-exposure prophylaxis (PEP), liquid suspension pediatric formulation and ST-357. PEP regimens are designed to prevent infection in individuals who have known or exposure to an infectious agent but are not symptomatic. The Company is developing a second mechanism of action smallpox small molecule antiviral drug that has shown efficacy in animal models of the disease.